Phase II trial of mitoguazone in patients with advanced squamous cell carcinoma of the head and neck.
We used mitoguazone (500 mg/m2 iv weekly, with 50-mg/m2 escalations weekly as tolerated) to treat 22 patients with squamous cell carcinoma of the head and neck which recurred after initial therapy. Nine of 22 (11%) patients responded: two had complete responses and seven had partial responses. Gastrointestinal toxicity and anemia were commonly seen. We conclude that mitoguazone is active in squamous cell carcinoma of the head and neck and should be incorporated into phase III trials.
D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006146:Guanidines / Q000627:therapeutic use*; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D008935:Mitoguazone / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis
D006146:Guanidines; D008935:Mitoguazone